Dexamethasone with Neomycin and Polymyxin B sulphate (Drops and ointment)
Dexamethasone 1 mg/gram with neomycin 3500 units/gram and polymyxin B sulfate 6000 unit per 1 gram in 3.5g eye ointment
Dexamethasone 1 mg/ml with hypromellose 5 mg/ml with neomycin (as neomycin sulfate) 3500 units/ml with polymyxin B sulfate 6000 units/ml in 5ml eye drops
Dexamethasone with Tobramycin (Drops)
Dexamethasone 1 mg/ml with tobramycin 3 mg/ml eye drops.
Non formulary in BaNES and Swindon
For the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy. In line with NICE TA301 Nov 2013. Patients need to have gained 10 or more ETDRS letters of visual acuity between baseline and month 36 to receive a further implant at month 36 according to NICE TA301.
Note: concurrent treatment to both eyes not recommended (SPC).
A single implant releases fluocinolone for up to 36 months.
Implantation may not be repeated more frequently than every 36 months due to lack of evidence base of benefit.
Prednisolone 0.5% with Neomycin 0.5%
Sodium cromoglicate preservative free
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
High Cost Drug Approval System
Traffic Light Status Information
RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.
Amber medicines are considered suitable for GP prescribing following specialist initiation or recommendation.
Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.
These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations.
Suitable for patient to be directed to buy themselves
Not currently used. We intend to include this TLS in future to highlight where a decision to use this medicine is under review.
(In use from Oct 2020) Used where a decision has been made by the BSW APC not to routinely commission this preparation for its licensed indications. Do not prescribe.
Not currently used. We intend to include this TLS in future to highlight where this medicine and indication is ONLY available through a Specialist Centre according to a NICE Highly Specialised Technology or NHSE Specialised Commission Circular / Policy.